{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:35:20Z","timestamp":1783629320728,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-34619-7","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:36:08Z","timestamp":1768480568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Yttrium-90 radioembolization for primary and metastatic liver tumors exhibiting arterial-phase hypovascularity"],"prefix":"10.1038","volume":"16","author":[{"given":"Mira","family":"Malavia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Eliason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas A.","family":"Eggers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Arne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Marchak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Lindquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Premal","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7388-7253","authenticated-orcid":false,"given":"Leigh","family":"Casadaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"issue":"2","key":"34619_CR1","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jvir.2020.08.006","volume":"32","author":"SF Stella","year":"2021","unstructured":"Stella, S. F., Noel-Lamy, M., Rogalla, P., Beecroft, R. & Rajan, D. K. Hepatic arterial blood flow modulation in patients with hepatocellular carcinoma: A pilot study of the influence of intraarterial norepinephrine assessed with CT perfusion. J. Vasc Interv Radiol. 32(2), 204\u2013210. https:\/\/doi.org\/10.1016\/j.jvir.2020.08.006 (2021).","journal-title":"J. Vasc Interv Radiol."},{"issue":"2","key":"34619_CR2","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jvir.2020.10.023","volume":"32","author":"H McGregor","year":"2021","unstructured":"McGregor, H. et al. Quantitative assessment of the hemodynamic effects of Intra-Arterial nitroglycerin on hepatocellular carcinoma using Two-Dimensional perfusion angiography. J. Vasc Interv Radiol. 32(2), 198\u2013203. https:\/\/doi.org\/10.1016\/j.jvir.2020.10.023 (2021).","journal-title":"J. Vasc Interv Radiol."},{"issue":"12","key":"34619_CR3","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.jvir.2009.08.013","volume":"20","author":"KT Sato","year":"2009","unstructured":"Sato, K. T. et al. The role of tumor vascularity in predicting survival after yttrium-90 radioembolization for liver metastases. J. Vasc Interv Radiol. 20(12), 1564\u20131569. https:\/\/doi.org\/10.1016\/j.jvir.2009.08.013 (2009).","journal-title":"J. Vasc Interv Radiol."},{"issue":"4","key":"34619_CR4","doi-asserted-by":"publisher","first-page":"746","DOI":"10.2214\/AJR.18.20499","volume":"213","author":"HO Kim","year":"2019","unstructured":"Kim, H. O. et al. Change in perfusion angiography during transcatheter arterial chemoembolization for hepatocellular carcinoma predicts Short-Term outcomes. AJR Am. J. Roentgenol. 213(4), 746\u2013754. https:\/\/doi.org\/10.2214\/AJR.18.20499 (2019).","journal-title":"AJR Am. J. Roentgenol."},{"issue":"3","key":"34619_CR5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.2214\/AJR.15.15767","volume":"207","author":"FE Boas","year":"2016","unstructured":"Boas, F. E. et al. Quantitative measurements of enhancement on preprocedure triphasic CT can predict response of colorectal liver metastases to radioembolization. AJR Am. J. Roentgenol. 207(3), 671\u2013675. https:\/\/doi.org\/10.2214\/AJR.15.15767 (2016).","journal-title":"AJR Am. J. Roentgenol."},{"issue":"Suppl 2","key":"34619_CR6","doi-asserted-by":"publisher","first-page":"104S","DOI":"10.2967\/jnumed.116.187229","volume":"58","author":"FE Boas","year":"2017","unstructured":"Boas, F. E., Bodei, L. & Sofocleous, C. T. Radioembolization of colorectal liver metastases: Indications, Technique, and outcomes. J. Nucl. Med. 58(Suppl 2), 104S\u201311S. https:\/\/doi.org\/10.2967\/jnumed.116.187229 (2017).","journal-title":"J. Nucl. Med."},{"issue":"1","key":"34619_CR7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jvir.2023.09.023","volume":"35","author":"CP Brunson","year":"2024","unstructured":"Brunson, C. P. et al. Measurement of the Tumor-to-Normal ratio for radioembolization of hepatocellular carcinoma: A prospective study comparing 2-Dimensional perfusion Angiography, Technetium-99m macroaggregated Albumin, and Yttrium-90 SPECT\/CT. J. Vasc Interv Radiol. 35(1), 94\u2013101. https:\/\/doi.org\/10.1016\/j.jvir.2023.09.023 (2024).","journal-title":"J. Vasc Interv Radiol."},{"issue":"7","key":"34619_CR8","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.2967\/jnumed.122.264996","volume":"64","author":"M Watanabe","year":"2023","unstructured":"Watanabe, M. et al. Voxel-Based dosimetry predicts hepatotoxicity in hepatocellular carcinoma patients undergoing radioembolization with (90)Y glass microspheres. J. Nucl. Med. 64(7), 1102\u20131108. https:\/\/doi.org\/10.2967\/jnumed.122.264996 (2023).","journal-title":"J. Nucl. Med."},{"issue":"1","key":"34619_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40658-022-00520-9","volume":"10","author":"J Orcajo Rincon","year":"2023","unstructured":"Orcajo Rincon, J. et al. Maximum tumor-absorbed dose measured by voxel-based multicompartmental dosimetry as a response predictor in yttrium-90 radiation segmentectomy for hepatocellular carcinoma. EJNMMI Phys. 10(1), 7. https:\/\/doi.org\/10.1186\/s40658-022-00520-9 (2023).","journal-title":"EJNMMI Phys."},{"issue":"1","key":"34619_CR10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni, R. & Llovet, J. M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 30(1), 52\u201360. https:\/\/doi.org\/10.1055\/s-0030-1247132 (2010).","journal-title":"Semin Liver Dis."},{"key":"34619_CR11","unstructured":"Common Terminology. Criteria for Adverse Events (CTCAE);Published online 2017."},{"issue":"5","key":"34619_CR12","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.jvir.2020.12.023","volume":"32","author":"A Villalobos","year":"2021","unstructured":"Villalobos, A. et al. Tumor-to-Normal ratio relationship between planning Technetium-99 macroaggregated albumin and posttherapy Yttrium-90 Bremsstrahlung SPECT\/CT. J. Vasc Interv Radiol. 32(5), 752\u2013760. https:\/\/doi.org\/10.1016\/j.jvir.2020.12.023 (2021).","journal-title":"J. Vasc Interv Radiol."},{"issue":"11","key":"34619_CR13","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.2967\/jnumed.116.173104","volume":"57","author":"S Gnesin","year":"2016","unstructured":"Gnesin, S. et al. Partition Model-Based 99mTc-MAA SPECT\/CT predictive dosimetry compared with 90Y TOF PET\/CT posttreatment dosimetry in radioembolization of hepatocellular carcinoma: A quantitative agreement comparison. J. Nucl. Med. 57(11), 1672\u20131678. https:\/\/doi.org\/10.2967\/jnumed.116.173104 (2016).","journal-title":"J. Nucl. Med."},{"issue":"5","key":"34619_CR14","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1007\/s00259-020-05163-5","volume":"48","author":"H Levillain","year":"2021","unstructured":"Levillain, H. et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur. J. Nucl. Med. Mol. Imaging. 48(5), 1570\u20131584. https:\/\/doi.org\/10.1007\/s00259-020-05163-5 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"34619_CR15","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1007\/s00259-021-05600-z","volume":"49","author":"M Weber","year":"2022","unstructured":"Weber, M. et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur. J. Nucl. Med. Mol. Imaging. 49(5), 1682\u20131699. https:\/\/doi.org\/10.1007\/s00259-021-05600-z (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"34619_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin, E. et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol. Hepatol. 6(1), 17\u201329. https:\/\/doi.org\/10.1016\/S2468-1253(20)30290-9 (2021).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"5","key":"34619_CR17","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/hep.31819","volume":"74","author":"R Salem","year":"2021","unstructured":"Salem, R. et al. Yttrium-90 radioembolization for the treatment of Solitary, unresectable HCC: the LEGACY study. Hepatology 74(5), 2342\u20132352. https:\/\/doi.org\/10.1002\/hep.31819 (2021).","journal-title":"Hepatology"},{"issue":"2","key":"34619_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2967\/jnumed.111.094235","volume":"53","author":"E Garin","year":"2012","unstructured":"Garin, E. et al. Dosimetry based on 99mTc-macroaggregated albumin SPECT\/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J. Nucl. Med. 53(2), 255\u2013263. https:\/\/doi.org\/10.2967\/jnumed.111.094235 (2012).","journal-title":"J. Nucl. Med."},{"issue":"22","key":"34619_CR19","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.1088\/0031-9155\/53\/22\/019","volume":"53","author":"P Flamen","year":"2008","unstructured":"Flamen, P. et al. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres. Phys. Med. Biol. 53(22), 6591\u20136603. https:\/\/doi.org\/10.1088\/0031-9155\/53\/22\/019 (2008).","journal-title":"Phys. Med. Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34619-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34619-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34619-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T09:16:01Z","timestamp":1770110161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34619-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["34619"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-34619-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Premal Trivedi has received consulting fees and honoraria from Boston Scientific, with payments made to his institution. Jonathan Lindquist has received consulting fees and honoraria from Boston Scientific Corp, and serves on the advisory board for Boston Scientific Corp, with payments made to his institution Leigh Casadaban has received consulting fees and honoraria from Boston Scientific Corp, with payments made to her institution.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4588"}}